Accendra Health Inc.
ACH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACH
Accendra Health Inc. is a home medical equipment and patient care products company that generated $613.2M in revenue in the first half of 2026 but carries a high debt load and negative equity.
Key risk: High debt and negative equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Accendra Health Inc. is a home medical equipment and patient care products company that generated $613.2M in revenue in the first half of 2026 but carries a high debt load and negative equity.
- Generated total revenue of $613.2M for the six months ended June 30, 2026 [sec].
- Reported a net loss of $89.1M for the six months ended June 30, 2026 [sec].
- Cash and equivalents stood at $7.7M as of June 30, 2026 [sec].
- Total debt was $1,718.1M as of June 30, 2026, with shareholders' equity of -$461.0M [sec].
- Completed the sale of its Products & Healthcare Services (P&HS) segment on December 31, 2025, retaining an equity stake [sec · filed 2026-04-02].
What works
- Revenue from continuing operations remains substantial at $613.2M for the first half of 2026, indicating a large ongoing business base [sec].
- The company generated $154M of operating cash flow from continuing operations in 2025, showing underlying cash generation ability [sec · filed 2026-04-02].
- Management expects to have sufficient liquidity from operating activities, financing sources, and the amended Receivables Sale Program to fund working capital and growth [sec_mda · as of 2026-05-11].
What to weigh
- The company has a high debt load of $1,718.1M and negative shareholders' equity of -$461.0M as of June 30, 2026, indicating significant financial leverage [sec].
- Net loss of $89.1M for the first half of 2026 reflects ongoing profitability challenges [sec].
- Revenue in key segments declined year-over-year in Q1 2026: diabetes -0.8%, sleep therapy -8.2%, home respiratory therapy -10.5% [sec_mda · as of 2026-05-11].
- The company faces risks from the separation from the P&HS business and transition off transition services [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Sale of P&HS segment completed December 31, 2025
“Completed sale of P&HS business to Platinum Equity on December 31, 2025 and retained equity stake”
SEC filings · April 2, 2026
Risks & what to watch (4)›
Key risks
- High debt and negative equity — Total debt of $1,718.1M and negative equity of -$461.0M as of June 30, 2026, creating financial risk [sec].
- Revenue declines in core segments — Q1 2026 revenue fell in diabetes (-0.8%), sleep therapy (-8.2%), and home respiratory therapy (-10.5%) [sec_mda · as of 2026-05-11].
- Separation and transition risks — Risks from separating from the P&HS business and transitioning off transition services [sec_mda · as of 2026-08-10].
- Competitive and pricing pressures — Increasing competitive and pricing pressures in the marketplace could impact margins [sec · filed 2026-04-02].
What to watch
- Ability to stabilize or reverse revenue declines in sleep therapy and home respiratory therapy segments [sec_mda · as of 2026-05-11].
- Progress on reducing debt and improving the negative equity position [sec].
- Successful completion of the Balance Sheet Optimization Transaction expected in Q2 2026 [sec_mda · as of 2026-05-11].
- Operational and financial results following the separation from the P&HS business [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Accendra Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Accendra Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
10.0 months
OCF -$26M · Net income -$89M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
142
Total value held
$151.4M
| Holder | Shares | Value |
|---|---|---|
| coliseum capital management, llc | 13,100,807 | $29.9M |
| vanguard capital management llc | 6,564,348 | $15.0M |
| blackrock, inc. | 5,235,300 | $11.9M |
| charles schwab investment management inc | 3,635,526 | $8.3M |
| bank of america corp /de/ | 3,407,075 | $7.8M |
| invenomic capital management lp | 3,368,975 | $7.7M |
| d. e. shaw & co., inc. | 3,311,601 | $7.6M |
| vanguard portfolio management llc | 2,651,152 | $6.0M |
| dimensional fund advisors lp | 2,606,620 | $5.9M |
| geode capital management, llc | 1,835,910 | $4.2M |
Showing top 10 of 142 institutional holders of Accendra Health Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 12, 2026- % of float
- 11.1%
- Days to cover
- 8.1
- Shares short
- 6,856,674
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Accendra Health Inc.?
Accendra Health Inc. is a home medical equipment and patient care products company that generated $613.2M in revenue in the first half of 2026 but carries a high debt load and negative equity.
Who is the CEO of Accendra Health Inc.?
Mr. Edward A. Pesicka is the chief executive officer of Accendra Health Inc. (ACH).
Where is Accendra Health Inc. headquartered?
Accendra Health Inc. (ACH) is headquartered in Glen Allen, VA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.